 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | PANDA-VAC / UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov) - May 11, 2023
P1, N=6, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jun 2023 --> Jun 2024
- | PANDA-VAC / UNC Lineberger Comprehensive Cancer Center
Trial completion date, Trial primary completion date: PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov) - May 19, 2022
P1, N=6, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jun 2023 --> Jun 2024 Trial completion date: Oct 2032 --> Jun 2033 | Trial primary completion date: Oct 2022 --> Jun 2023
- | PANDA-VAC / UNC Lineberger Comprehensive Cancer Center
Trial completion date, Trial primary completion date: PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov) - Jul 8, 2021
P1, N=6, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial completion date: Oct 2032 --> Jun 2033 | Trial primary completion date: Oct 2022 --> Jun 2023 Trial completion date: Apr 2031 --> Oct 2032 | Trial primary completion date: Apr 2021 --> Oct 2022
- | PANDA-VAC / UNC Lineberger Comprehensive Cancer Center
Trial initiation date: PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov) - Mar 31, 2020
P1, N=6, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial completion date: Apr 2031 --> Oct 2032 | Trial primary completion date: Apr 2021 --> Oct 2022 Initiation date: Feb 2020 --> Sep 2020
- | PANDA-VAC / UNC Lineberger Comprehensive Cancer Center
New P1 trial: PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov) - Feb 11, 2020
P1, N=6, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center